239 related articles for article (PubMed ID: 15963209)
1. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
Bullock R; Dengiz A
Int J Clin Pract; 2005 Jul; 59(7):817-22. PubMed ID: 15963209
[TBL] [Abstract][Full Text] [Related]
2. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Doody RS
J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
4. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
5. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
6. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
7. Effective pharmacological management of Alzheimer's disease.
Atri A
Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
9. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
[TBL] [Abstract][Full Text] [Related]
10. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
Harry RD; Zakzanis KK
Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
12. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
13. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
14. Realistic expectations for treatment success in Alzheimer's disease.
Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
[TBL] [Abstract][Full Text] [Related]
15. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Beier MT
Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
[TBL] [Abstract][Full Text] [Related]
17. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
Farlow MR; Lilly ML;
BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242
[TBL] [Abstract][Full Text] [Related]
19. Drug therapy of dementia in elderly patients. A review.
Olsen CE; Poulsen HD; Lublin HK
Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]